Literature DB >> 14824408

Sustained hypertension following the administration of desoxycorticosterone acetate.

S M FRIEDMAN, C L FRIEDMAN, M NAKASHIMA.   

Abstract

DCA was administered in two separate experiments to rats in amounts sufficient to cause marked elevation of the blood pressure. It was then abruptly withdrawn. Following this treatment, observations of blood pressure, blood urea nitrogen, plasma potassium, and plasma volume were carried out for over a year. Approximately one-third of the animals so treated developed a sustained, permanent hypertension after treatment had been stopped. This sustained hypertension is not due to any anatomical fault in the kidney and in that sense is not primarily renal in origin. An hypothesis to explain the findings is presented.

Entities:  

Keywords:  ADRENAL CORTEX HORMONES; BLOOD PRESSURE, HIGH

Mesh:

Substances:

Year:  1951        PMID: 14824408      PMCID: PMC2136078          DOI: 10.1084/jem.93.4.361

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  A plethysmographic method for measuring systolic blood pressure in the intact rat.

Authors:  F B Byrom; C Wilson
Journal:  J Physiol       Date:  1938-08-15       Impact factor: 5.182

2.  Persistence of desoxycorticosterone-induced hypertension in the nephrectomized rat.

Authors:  C E HALL; O HALL
Journal:  Proc Soc Exp Biol Med       Date:  1949-08

3.  A hypertensive syndrome with relative adrenal cortical overactivity.

Authors:  D F DAVIES; H E CLARK
Journal:  Circulation       Date:  1950-10       Impact factor: 29.690

4.  Self-sustained hypertension in the albino rat; a hypothesis to explain it.

Authors:  S M FRIEDMAN; C L FRIEDMAN
Journal:  Can Med Assoc J       Date:  1949-12       Impact factor: 8.262

5.  Conversion of desoxycorticosterone acetate to progesterone in vivo.

Authors:  M X ZARROW; F L HISAW; F BRYANS
Journal:  Endocrinology       Date:  1950-04       Impact factor: 4.736

6.  Some observations on methods of determining blood pressure in the rat.

Authors:  S M FRIEDMAN; C L FRIEDMAN
Journal:  Rev Can Biol       Date:  1949-12

7.  Observations on the role of the rat kidney in hypertension caused by desoxycorticosterone acetate.

Authors:  S M FRIEDMAN; C L FRIEDMAN
Journal:  J Exp Med       Date:  1949-06-01       Impact factor: 14.307

8.  The effect of desoxycorticosterone acetate on blood pressure, renal function, and electrolyte pattern in the intact rat.

Authors:  S M FRIEDMAN; J R POLLEY; C L FRIEDMAN
Journal:  J Exp Med       Date:  1948-04-01       Impact factor: 14.307

  8 in total
  7 in total

1.  Aldosterone secretion and primary and malignant hypertension.

Authors:  J H LARAGH; S ULICK; V JANUSZEWICZ; Q B DEMING; W G KELLY; S LIEBERMAN
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  The granulation of juxtaglomerular cells in renal hypertension, desoxycorticosterone and postdesoxycorticosterone hypertension, adrenal regeneration hypertension, and adrenal insufficiency.

Authors:  L TOBIAN; J THOMPSON; R TWEDT; J JANECEK
Journal:  J Clin Invest       Date:  1958-05       Impact factor: 14.808

3.  Renal function in primary aldosteronism.

Authors:  A C CORCORAN; H P DUSTAN; I H PAGE
Journal:  J Clin Invest       Date:  1956-12       Impact factor: 14.808

4.  Juxtaglomerular cells, renal pressor substances and nephrosclerosis.

Authors:  G M MASSON
Journal:  Experientia       Date:  1962-05-15

5.  The contribution of the sympathetic nervous system to the development and maintenance of experimental hypertension in the rat.

Authors:  L Finch; G D Leach
Journal:  Br J Pharmacol       Date:  1970-06       Impact factor: 8.739

6.  Recovery of adrenal ultrastructure after cessation of androgen treatment.

Authors:  P A Nickerson; A Molteni
Journal:  Am J Pathol       Date:  1971-07       Impact factor: 4.307

7.  Effects of chronic excess salt feeding. Induction of self-sustaining hypertension in rats.

Authors:  L K DAHL
Journal:  J Exp Med       Date:  1961-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.